Sepracor reduces stake in BioSphere Medical:
This article was originally published in Clinica
BioSphere Medical, a Nasdaq-quoted US company which is developing embolotherapy and non-embolotherapy applications for its proprietary bioengineered acrylic beads, is to offer four million shares at $11 a share. Two million come from pharmaceuticals manufacturer Sepracor, which presently owns more than 50% of BioSphere. Sepracor has seen its own share price fall from $138.25 to less than $38 in the past 52 weeks.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.